Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2011
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2011
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2011
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2010
Lead Product(s) : Amrubicin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable